Market Overview

UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT on HeartWare International

Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking

In a report published Monday, Goldman Sachs Group reiterated its Neutral rating on HeartWare International (NASDAQ: HTWR), but lowered its price target from $86.00 to $84.00.

Goldman Sachs noted, “Following a detailed review of the left ventricular assist device market, we maintain our Neutral rating on shares of HTWR. We reduce our 2013-2016 revenue estimates to reflect a slower launch of the company's recent US approval for the HVAD device. Longer-term, we continue to have a bullish view on LVADs in general (we model +19% growth through 2016E) and see HeartWare as an attractive fundamental and strategic asset. However, over the near-term we think expectations for the company's US product launch need to be reset. We think HTWR will remain range-bound, as we would also not expect to see material downside unless we developed strong conviction that its long-term growth prospects (primarily approval for Destination Therapy) are in jeopardy.”

HeartWare International closed on Friday at $82.31.

Latest Ratings for HTWR

Aug 2015Credit SuisseAssumesOutperform
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015BarclaysMaintainsOverweight

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings


Related Articles (HTWR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters